To Market, To Market – 2005

Publisher Summary This chapter discusses 22 new chemical entities (NCEs) and two new biological entities (NBEs) manufactured in the year 2005. In the anti-infective therapeutic area five new drugs were introduced—Tygacil™ (tigecycline), Aptivus ® (tipranavir), Ebernets (eberconazole), Lulicon ® (luliconazole), and Finibax (doripenem). In the area of the central nervous system (CNS), there are five marketed drugs—Prialt ® (ziconotide), Prexige ® (lumiracoxib), Lunesta™ (eszopiclone), Rozerem™ (ramelteon), and Azilect ® (rasagiline). The oncolytic domain included Clolar™ (clofarabine), Amnolake ® (tamibarotene), Nexavar ® (sorafenib), and Kepivance™ (palifermin). The field of antidiabetics saw the introduction to Apidra ® (insulin glulisine), Symlin ® (pramlintide), Byetta™ (exenatide), Oral-Lyn™, and Naglazyme™ (galsulfase). The ophthalmic sector welcomed two NCEs: Macugen ® (pegaptanib) and Nevanac™ (nepafenac). The other therapeutic area with two new introductions to the market was renal-urologic. In addition to the NCEs and NBEs described in the chapter, 2005 was a notably productive year for the introduction of new vaccines.